David Cunningham

Has grant

Professor Cancer Medicine

Institute of Cancer Research
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Novel blood test to personalise Early Stage Colorectal Cancer treatment

Open Date: 2020-01-01

Close Date: 2027-12-31

Grant: Close

NIHR Royal Marsden Biomedical Research Centre

Open Date: 2012-04-01

Close Date: 2017-03-31

Grant: Close

CRUKE/11/020: CHEMO-T: CHOP verses GEM-P in the first line treatment Of T-cell Lymphoma

Open Date: 2011-10-01

Close Date: 2018-09-30

Grant: Close

CRUK/08/029: DLBCL: Feasibility study of R-CHOP plus Bevacizumab in patients with diffuse large B-cell Lymphoma

Open Date: 2008-06-01

Close Date: 2010-05-31

Grant: Close

CRUKE/07/049: REAL3: A randomized open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophagogastric cancer

Open Date: 2007-09-01

Close Date: 2012-08-31

Articles (29)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.

Year:

2026

Year:

2026

Objectives To evaluate the feasibility, safety, and technical performance of robot-assisted CT-guided cryoablation for pulmonary metastases. Materials and methods A single-centre IDEAL stage 2a prospective development study of 26 participants (median age 62 years, IQR 47–71; 14 men) who underwent 30 procedures targeting 37 lung metastases using a robotic navigation system. Median tumour diameter was 9.8 mm (IQR 5.1–12.8). All procedures were performed under general anaesthesia with high-frequency jet ventilation. Feasibility, safety, and technical performance (targeting accuracy, manipulations, radiation dose) were recorded. Results Robotic guidance was successfully completed without conversion in 35/37 tumours (95%). One major complication occurred (3%, CTCAE grade 3 pneumothorax requiring 4 days of drainage); all others were grade 1–2. Pneumothoraces were managed by observation ( n = 7) or prophylactic intraprocedural chest drain insertion ( n = 11). No bronchopleural fistulas were observed. Median hospital stay was 1 night (IQR 1–2). A total of 54 cryoprobes were used. Median Euclidean targeting error on first insertion was 6.1 mm (IQR 2.9–9.7) and lateral error 4.2 mm (IQR 2.2–6.5). The median number of manipulations per probe was 1 (IQR 0–2.5), with one-third requiring no adjustment. Once integrated into the workflow, the “chopstick” technique was frequently applied, supporting conformal ablation. Median total procedure time was 66.5 min (IQR 56.6–92.8). Twelve-month local tumour progression-free survival was 97%. Conclusion Robot-assisted CT-guided cryoablation of pulmonary metastases was feasible, safe, and accurate, achieving high targeting precision with minimal cryoprobe manipulation. These findings support evaluation in prospective comparative trials. Key Points Question Robotic-assisted CT-guided cryoablation of lung metastases is feasible and safe, achieving high targeting accuracy and minimal probe manipulation, even in anatomically challenging cases. Findings Robotic trajectory planning supported complex multiprobe configurations. Procedural refinements—including patient positioning, probe selection, and adoption of “chopstick” configurations—were introduced to address bleeding risk and optimise energy delivery. Clinical relevance Robot-assisted navigation is particularly advantageous in cryoablation, enabling minimal manipulations and accurate probe placement despite the often-necessary complex trajectories. Graphical Abstract

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (37)

John Bridgewater

UCL Cancer Institute

UNITED KINGDOM
View details

Chan Yoon Cheah

University of Western Australia

AUSTRALIA
View details

David Cairns

Professor of Clinical Trials Research

University of Leeds

UNITED KINGDOM
View details

Heike I Grabsch

Professor

University of Leeds

UNITED KINGDOM
View details

Jae-Ho Cheong

Professor

Yonsei University College of Medicine

SOUTH KOREA
View details

David J. Pinato

Imperial College London

UNITED KINGDOM
View details

Henry Woodruff

Associate Professor

University of Maastricht

NETHERLANDS
View details

Andrew H. Briggs

London School of Hygiene & Tropical Medicine

UNITED KINGDOM
View details

Guglielmo Vetere

Assistant Professor - Gastrointestinal Medical Oncology

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yasmin Karimi

University of Michigan

UNITED STATES
View details

Edward Johnston

Institute of Cancer Research

UNITED KINGDOM
View details

Filippo Pietrantonio

Researcher (non-academic)

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY
View details

nicola valeri

Reader and Team Leader

Institute of Cancer Research

UNITED KINGDOM
View details

Alessio Cortellini

Imperial College London

UNITED KINGDOM
View details

Derek Magee

Associate Professor

University of Leeds

UNITED KINGDOM
View details

david tougeron

-

FRANCE
View details

Caroline Kelly

Head of Biostatistics

-

UNITED KINGDOM
View details

Josep Tabernero

Associate Professor Faculty of Medicine

Universitat de Vic - Universitat Central de Catalunya

SPAIN
View details

Michiel Henkens

Maastricht University Medical Centre

NETHERLANDS
View details

Ian Chau

Royal Marsden Hospital Sutton

UNITED KINGDOM
View details

Muti Abulafi

-

UNITED KINGDOM
View details

Michele Ghidini

Docenti di ruolo di IIa fascia

University of Insubria

ITALY
View details

Jayne Tierney

University College London

UNITED KINGDOM
View details

Luca Magnani

Docenti

University of Milan

ITALY
View details

Manuel Salto-Tellez

Lead

Institute of Cancer Research

UNITED KINGDOM
View details

Matteo Fassan

Docenti di ruolo di Ia fascia

University of Padova

ITALY
View details

Naureen Starling

Reader

Institute of Cancer Research

UNITED KINGDOM
View details

Leslie Samuel

University of Aberdeen

UNITED KINGDOM
View details

Jan Walewski

Professor of Medicine, Consultant in Medical Oncology

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Sara Lonardi

Head of Dept

Istituto Oncologico Veneto

ITALY
View details

Ruth Langley

University College London

UNITED KINGDOM
View details

Chiara Braconi

Chair in HepatoBiliary Oncology

University of Glasgow

UNITED KINGDOM
View details

Jamie Stokes

University of Oxford

UNITED KINGDOM
View details

Martin Hutchings

Professor

University of Copenhagen

DENMARK
View details

Chiara Cremolini

University Hospital of Pisa

ITALY
View details

Hyunki Kim

Professor

Yonsei University College of Medicine

SOUTH KOREA
View details

Lucinda Billingham

Professor of Biostatistics

University of Birmingham

UNITED KINGDOM
View details